bioRxiv Science⌕ Search

Biology subjects

Renault, S.

Publications and source records attributed to Renault, S..

3 recordsLinked to original sources

Ultrafast tyrosine-based cell membrane modification via diazonium salts: a new frontier for biomedical applications

In this study, we present an ultrafast, efficient, and broadly applicable strategy for cell membrane modification via tyrosine bioconjugation using diazonium salt derivatives. This chemical approach enables both one-step and two-step functionalization of adherent, suspension, and primary cells with diverse ligands, including imaging probes, carbohydrates, biotin, and proteins, without inducing cytotoxicity or immune activation. Membrane engineering through bioconjugation is emerging as a valuable tool in biomedical research, given the cell membranes central role in signaling, transport, and cell-cell interactions. Compared to traditional glyco-engineering methods that often require multiday incubations and can cause cellular stress, our approach achieves precise and high-density grafting in less than one hour, with improved reproducibility and biological compatibility. Importantly, we demonstrate that this strategy can be applied to a variety of cell types, encompassing both immortalized cell lines and primary cells, notably Peripheral Blood Mononuclear Cells (PBMCs) and human effector cells such as natural killer (NK) cells, to enhance their cytotoxic function against EGFR-positive cancer cells via surface-conjugated Nanofitin. Moreover, we show that the bioconjugated signal diminishes over time due to cell division, offering a self-limiting alternative to permanent genetic modifications such as CAR-T, thereby mitigating risks associated with overly prolonged immune activation. Finally, the feasibility of storing pre-functionalized cells at -80 {degrees}C expands the practicality of this platform for future ready-to-use applications. Together, these features make our method a compelling alternative to current technologies for applications in targeted therapy, diagnostics, and cell-based immunotherapy.

bioengineering↗

Functional assessment of a kcnb1 knock-out zebrafish to model KCNB1-related neurodevelopmental and epileptic disorders

KEY POINTSO_LIkcnb1 is expressed in distinct cell subtypes and various regions of the central nervous system in zebrafish C_LIO_LIBrain anatomy and neuronal circuits are not disrupted in the kcnb1 loss-of-function zebrafish model C_LIO_LILoss of kcnb1 leads to altered behavior phenotype, light and sound-induced locomotor impairments C_LIO_LIkcnb1 knock-out zebrafish exhibit increased locomotor sensitivity to PTZ and elevated expression of epileptogenesis-related genes C_LIO_LIkcnb1-/- larvae show spontaneous and provoked epileptiform-like electrographic activity associated with disrupted GABA regulation C_LI ObjectiveKCNB1 encodes an -subunit of the delayed-rectifier voltage-dependent potassium channel Kv2.1. De novo pathogenic variants of KCNB1 have been linked to developmental and epileptic encephalopathies (DEE), diagnosed in early childhood and sharing limited treatment options. Loss-of-function (LOF) of KCNB1 with dominant negative effects has been proposed as the pathogenic mechanism in these disorders. Here, we aim to characterize a knock-out (KO) zebrafish line targeting kcnb1 (kcnb1+/- and kcnb1-/-) for investigating DEEs. MethodsThis study presents the phenotypic analysis of a kcnb1 knock-out zebrafish model, obtained by CRISPR/Cas9 mutagenesis. Through a combination of immunohistochemistry, behavioral assays, electrophysiological recordings, and neurotransmitter quantifications, we have characterized the expression, function, and impact of this kcnb1 LOF model at early stages of development. ResultsIn wild-type larval zebrafish, kcnb1 was found in various regions of the central nervous system and in diverse cell subtypes including neurons, oligodendrocytes and microglial cells. Both kcnb1+/- and kcnb1-/- zebrafish displayed impaired swimming behavior and "epilepsy-like" features that persisted through embryonic and larval development, with variable severity. When exposed to the chemoconvulsant pentylenetetrazol (PTZ), both mutant models showed elevated locomotor activity. In addition, PTZ-exposed kcnb1-/- larvae exhibited higher bdnf mRNA expression and activated c-Fos positive neurons in the telencephalon. This same model presents spontaneous and provoked epileptiform-like electrographic activity associated with disrupted GABA regulation. In this KO model, neuronal circuit organization remained unaffected. SignificanceWe conclude that kcnb1 knock-out in zebrafish leads to early-onset phenotypic features reminiscent of DEEs, affecting neuronal functions and primarily inhibitory pathways in developing embryonic and larval brains. This study highlights the relevance of this model for investigating developmental neuronal signaling pathways in KCNB1-related DEEs.

neuroscience↗

Cryopreserved cGMP-compliant human pluripotent stem cells-derived immature hepatic progenitors rescue mice from acute liver failure

Liver transplantation remains the only curative treatment for end-stage liver diseases. Unfortunately, there is a drastic organ donor shortage. Hepatocyte transplantation emerged as a viable alternative to liver transplantation. In light of their unique expansion capabilities and their potency to be driven towards a chosen cell fate, pluripotent stem cells (PSC) are extensively studied as an unlimited cell source of hepatocytes for cell therapy. It has been previously shown that freshly prepared hepatocyte-like cells can cure mice from acute and chronic liver failures and restore liver functions. In this study, we generated human PSC-derived immature hepatic progenitors (GStemHep) using current good manufacturing practice (cGMP) compliant conditions from PSC amplification, hepatic differentiation to cell cryopreservation. These GStemHep cells present an immature hepatic phenotype (alpha-fetoprotein positive, albumin negative), secrete hepatocyte growth factor (HGF) and do not express MHC type I or II. The therapeutic potential of GStemHep was assessed in two clinically relevant models of acute liver failure. A single dose of thawed GStemHep rescue mice from sudden death caused by acetaminophen and thioacetamide-induced acute live failure, both in immunodeficient and immunocompetent animals in absence of immunosuppression. The mode of action was studied by several analytical methods including unbiased proteomic analyses. The swiftness of the therapeutic effect suggests a paracrine mechanism of action of GStemHep leading to a rapid reduction of inflammation and a rapid cytoprotective effect. Therapeutic biological effects were observed as soon as 3 hours post-cell transplantation with reduction in serum transaminases and in liver necrosis. Mode of action of GStemHep relies on alleviation of inhibition factors of liver regeneration, increase in proliferationpromoting factors and decrease liver inflammation. In conclusion, we generated cGMP-compliant human PSC-derived immature hepatic progenitors that were highly effective in treating acute liver failure. This is also the first report highlighting that human allogeneic cells could be used as cryopreserved cells and in absence of immunosuppression for a human PSC-based regenerative medicine of acute liver injuries.

cell biology↗